Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 6/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.56 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.56 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.56 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5889303 | 0.86 | MEN1 (0.41) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL1715026 | 0.86 | GRIN1 (0.53) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Hydrochloric Acid SCHEMBL908947 | 0.84 | GRIN1 (0.51) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Hydrochloric Acid SCHEMBL16678441 | 0.78 | GRIN1 (0.51) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Hydrochloric Acid SCHEMBL7113114 | 0.78 | GRIN1 (0.59) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL1150391 | 0.76 | GRIN1 (0.61) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL1239130 | 0.76 | EPHX2 (0.56) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL5889274 | 0.76 | GRIN1 (0.46) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Iodide SCHEMBL1714835 | 0.75 | EPHX2 (0.54) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Hydrochloric Acid SCHEMBL7110650 | 0.73 | MEN1 (0.59) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1903028-A1 | Conjugates of glutamate and NMDA receptor channel blockers without excito-toxic effects | Tschollar,, Werner (CH) | 2008-03-26 | — | — | EP | claimed |
| EP-1512679-B1 | Novel adamantane derivatives with neuroprotective, antidepressant and anti-ischaemic activities, and process for preparing them | ROTTAPHARM SPA (IT) | 2011-07-20 | — | — | EP | disclosed |
| EP-1903028-A1 | Conjugates of glutamate and NMDA receptor channel blockers without excito-toxic effects | Tschollar,, Werner (CH) | 2008-03-26 | — | — | EP | disclosed |
| US-7145037-B2 | Adamantane derivatives with neuroprotective, antidepressant and anti-ischaemic activities, and process for preparing them | ROTTA RESEARCH LABORATURIUM S.P.A. (IT) | 2006-12-05 | — | — | US | disclosed |
| EP-1512679-A1 | Novel adamantane derivatives with neuroprotective, antidepressant and anti-ischaemic activities, and process for preparing them | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 2005-03-09 | — | — | EP | disclosed |
| US-20050049312-A1 | Novel adamantane derivatives with neuroprotective, antidepressant and anti-ischaemic activities,and process for preparing them | ROTTA RESEARCH LABORATORIUM S.P.A. | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049312-A1 | Novel adamantane derivatives with neuroprotective, antidepressant and anti-ischaemic activities,and process for preparing them | BDNF, NLN, GAP43 | GRIN1 9/4885GRIN2A 14/4885GRIN2D 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.